Advertisement
News
Advertisement

Isis Pharmaceuticals to Present at Leerink Swann's 2012 Global Healthcare Conference

Wed, 02/08/2012 - 2:45am
The Associated Press

/FROM PR NEWSWIRE DALLAS 888-776-3971/

STK NASDAQ-NMS:ISIS

IN HEA MEQ

SU TDS

TO BUSINESS, AND HEALTH EDITORS:

Isis Pharmaceuticals to Present at Leerink Swann's 2012 Global

Healthcare Conference

CARLSBAD, Calif., Feb. 8, 2012 /PRNewswire/ -- Isis Pharmaceuticals,

Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today

announced that management will present a company overview at Leerink

Swann's 2012 Global Healthcare Conference on Wednesday, February 15,

2012 at 2:30 p.m. ET at the Waldorf Astoria in New York City.

A live audio webcast of the presentation will be available on the

"Investors & Media" section of the Company's Web site,

www.isispharm.com. A replay of the presentation will be available on

the Isis Web site within 48 hours and will be archived for a limited

time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to

discover and develop novel drugs for its product pipeline and for its

partners. Isis' broad pipeline consists of 26 drugs to treat a wide

variety of diseases with an emphasis on cardiovascular, metabolic,

severe and rare diseases, and cancer. Isis' partner, Genzyme, plans

to commercialize Isis' lead product, mipomersen, following regulatory

approval, which is expected in 2012. Isis' patents provide strong and

extensive protection for its drugs and technology. Additional

information about Isis is available at www.isispharm.com.

SOURCE Isis Pharmaceuticals, Inc.

-0- 02/08/2012

/CONTACT: Kristina Lemonidis, Director, Corporate Communications, +1-760-603-2490, or Amy Blackley, Ph.D., Assistant Director, Corporate Communications, +1-760-603-2772, both for Isis Pharmaceuticals, Inc.

/Web Site: http://www.isispharm.com

(NASDAQ-NMS:ISIS) /

CO: Isis Pharmaceuticals, Inc.

ST: California

IN: HEA MEQ

SU: TDS

PRN

-- LA49577 --

0000 02/08/2012 12:00:00 EDT http://www.prnewswire.com

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading